Deubiquitinase Ubiquitin‐Specific Protease 29 Ameliorates Pathological Cardiac Hypertrophy through Inhibiting Transforming Growth Factor β‐Activated Kinase 1
Here, we have identified USP29 as a novel negative regulator of pathological cardiac hypertrophy. Our findings suggest that targeting either USP29 or its interaction with TAK1 could represent an innovative therapeutic strategy for treating heart failure and cardiac hypertrophy.
Authors
- Tiesheng Niu (ORCID: https://orcid.org/0000-0003-1263-9541)
- Hongjie Shi (ORCID: https://orcid.org/0009-0008-7917-3241)
- Yufeng Hu (ORCID: https://orcid.org/0000-0002-9416-262X)
- Zhen Liu (ORCID: https://orcid.org/0000-0002-1559-6543)
- Zefeng Xu (ORCID: https://orcid.org/0000-0002-1581-7027)
- Jianqing Zhang (ORCID: https://orcid.org/0000-0002-5822-2218)
- Yan Sun (ORCID: https://orcid.org/0000-0002-5229-2485)
- Xi Jiang (ORCID: https://orcid.org/0000-0003-4770-8818)
Institutions
- Wuhan University (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1161/jaha.124.034962
- Citations
- 1
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81